AstraZeneca's NIAGARA Phase 3 Trial Of Imfinzi (Durvalumab) Plus Chemotherapy Showed Statistically Significant And Clinically Meaningful Improvement In Event-free Survival And Overall Survival Vs Neoadjuvant Chemotherapy In Muscle-invasive Bladder Cancer
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's NIAGARA Phase 3 trial of Imfinzi (Durvalumab) combined with chemotherapy demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival compared to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
June 25, 2024 | 8:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's NIAGARA Phase 3 trial results for Imfinzi (Durvalumab) plus chemotherapy showed significant improvements in survival rates for muscle-invasive bladder cancer, which could positively impact the company's stock price.
The positive results from the NIAGARA Phase 3 trial indicate that Imfinzi (Durvalumab) combined with chemotherapy is more effective than neoadjuvant chemotherapy alone in treating muscle-invasive bladder cancer. This could lead to increased adoption of Imfinzi, boosting AstraZeneca's revenues and positively impacting its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100